fbpx

What a promising clinical trial of Urolithin A tells us about brain circulation, cellular energy, and the importance of keeping our brain’s immune cells working for us.

When we think about protecting our brains from Alzheimer’s disease and other forms of cognitive decline, we often focus on what might be going wrong: accumulating amyloid, inflammation, or the loss of neurons. But what if an equally important question is whether our brain cells have the energy they need to function properly?

A fascinating new study, published October 9, 2026, in JAMA Network Open, brings this question into focus. Researchers investigated whether improving mitochondrial health could positively influence blood flow in the brain. Their findings offer an intriguing glimpse into a fundamentally different approach to brain health.

Scientists at the University of Oklahoma conducted a randomized, double-blind, placebo-controlled clinical trial involving 50 adults between the ages of 40 and 64 with obesity, a condition associated with mitochondrial dysfunction, inflammation, and increased risk for cognitive decline.

Participants received either a placebo or 1,000 milligrams daily of urolithin A, a naturally occurring compound produced when certain gut bacteria metabolize polyphenols found in foods such as pomegranates and walnuts.

Urolithin A is particularly interesting because it stimulates mitophagy, the cellular process responsible for identifying and recycling damaged mitochondria.

Over four weeks, researchers measured vascular function throughout the body and, importantly, changes in brain blood flow during memory-related tasks.

The results were surprising. While urolithin A did not significantly improve blood vessel function in the arms or hands, it produced a statistically significant increase in the brain’s blood-flow response during cognitive activity.

This improvement was particularly evident in a brain region critically involved in working memory and executive function.

In other words, when participants challenged their brains with demanding mental tasks, those receiving urolithin A demonstrated a stronger vascular response, meaning improved delivery of blood to regions engaged in cognitive processing.

Importantly, the researchers did not demonstrate improvements in actual memory performance. Nor did they directly establish that mitochondrial function improved within the brain. These distinctions matter, particularly in a relatively small, four-week study.

Nevertheless, the findings raise an important possibility: targeting mitochondrial health may help improve the brain’s ability to respond to metabolic demands.

This research connects directly with a central theme of my book, Brain Defenders.

Our brains contain specialized immune cells called microglia. Far from being simply inflammatory cells, microglia are indispensable guardians of brain health. They continuously survey their surroundings, remove cellular debris, support neuronal connections, and help maintain a healthy brain environment.

But their behavior is profoundly influenced by their metabolic state.

When microglial mitochondria are functioning efficiently, these cells are better equipped to carry out their protective responsibilities. When mitochondrial function deteriorates, microglia may shift toward dysfunctional, pro-inflammatory states.

This is the emerging science of immunometabolism: the recognition that cellular energy metabolism helps determine how immune cells behave.

Mitochondrial dysfunction can amplify oxidative stress and inflammatory signaling, potentially encouraging microglia to contribute to the very neurodegenerative processes they ordinarily help prevent.

Mitophagy is therefore especially relevant. By clearing damaged mitochondria, cells can potentially reduce metabolic stress and maintain a healthier mitochondrial population.

Interestingly, earlier laboratory research has demonstrated that urolithin A can influence inflammatory responses and metabolism in microglial cells. The current human study did not measure microglial activity, but its findings are consistent with the broader scientific rationale for investigating mitochondrial quality control as a brain-protective strategy.

The implications extend well beyond urolithin A. We are beginning to recognize that brain degeneration is not simply a consequence of accumulating abnormal proteins. It also reflects disturbances in energy production, immune regulation, vascular function, and the intricate communication among these systems.

Exercise, for example, promotes mitochondrial adaptation and supports metabolic health. Urolithin A, as I described in Brain Defenders, represents another potential avenue for pursuing mitochondrial quality control. And that matters a lot. In addition, I reference earlier human research demonstrating improvements in muscle strength and endurance following urolithin A supplementation.

Urolithin A is now commercially available as a nutritional supplement, offering a way to obtain the compound directly without depending on whether your particular gut microbiome can produce it. Human studies have investigated daily doses ranging from 500 to 1,000 milligrams, including the 1,000-milligram dose used in this new brain vascular study.